MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ
0.4201
+0.0031
+0.74%
Opening 09:57 03/28 EDT
OPEN
0.4200
PREV CLOSE
0.4170
HIGH
0.4600
LOW
0.4182
VOLUME
13.35K
TURNOVER
0
52 WEEK HIGH
1.393
52 WEEK LOW
0.4120
MARKET CAP
42.96M
P/E (TTM)
-2.7693
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TLSA last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at TLSA last week (0311-0315)?
Weekly Report · 03/18 09:36
Weekly Report: what happened at TLSA last week (0304-0308)?
Weekly Report · 03/11 09:36
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 55.9% to $0.07 during Tuesday's pre-market session. CASI Pharmaceuticals (NASdaq:CASI) shares rose 47.68% in the pre- market session. Regenxbio (NASDA:RGNX) and Apogee Therapeutics also moved upwards. Losers Lipella Pharmaceuticals and Ekso Bionics Holdings.
Benzinga · 03/05 13:09
Weekly Report: what happened at TLSA last week (0226-0301)?
Weekly Report · 03/04 09:37
Weekly Report: what happened at TLSA last week (0219-0223)?
Weekly Report · 02/26 09:40
Weekly Report: what happened at TLSA last week (0212-0216)?
Weekly Report · 02/19 09:40
UPDATE 2-European, US carmakers race to lower EVs costs as China competition heats up
European, US carmakers race to lower EVs costs as China competition heats up. Major U.S. And European carmakers are pushing hard to cut electric vehicle costs. They are under pressure from lower-cost Chinese competitors. The high cost of EVs has become a barrier to mass adoption.
Reuters · 02/15 13:23
More
About TLSA
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Webull offers Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ: TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.